Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor

References

• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8: 299–308.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666–75.
   PubMed Web of Science ®Google Scholar
• Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol. 2006;24:5576–83.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168–73.
   PubMed Web of Science ®Google Scholar
• Yee J, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, . Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med. 2000;192:1637–44.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24: 5060–9.
   PubMed Web of Science ®Google Scholar
• Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer. 2002;2:627–33.
   PubMed Web of Science ®Google Scholar
• Weng NP, Palmer LD, Levine BL, Lane HC, June CH, Hodes RJ. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev. 1997;160: 43–54.
   PubMed Web of Science ®Google Scholar
• Roth A, Yssel H, Pene J, Chavez EA, Schertzer M, Lansdorp P, . Telomerase levels control the lifespan of human T lymphocytes. Blood. 2003;102;849–57.
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, . Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1. New Eng J Med. 2008;358:2698–703.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–24.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubistein L, . New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, . GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy. 2007;9:499–507.
   PubMed Web of Science ®Google Scholar
• Freshney RI. Induction of differentiation in neoplastic cells. Anticancer Res. 1985;5:111–6.
   PubMed Web of Science ®Google Scholar
• Montagna D, Schiavo R, Gibelli N, Pedrazzoli P, Tonelli R, Pagani S, . Ex vivo generation of anti-tumor cytotoxic T-cell lines derived from patients and their HLA-identical sibling. Int J Cancer. 2004;110:76–86.
   PubMedGoogle Scholar
• Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, . Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266: 2011–5.
   PubMed Web of Science ®Google Scholar
• Villa R, Folini M, Perego P, Supino R, Setti E, Daidone MG, . Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents. Int J Oncol. 2000;16:995–1002.
   PubMed Web of Science ®Google Scholar
• Lisini D, Zecca M, Giorgiani G, Montagna D, Cristantielli R, Labirio M, . Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA- identical sibling. Hematologica. 2008;93:1859–67.
   PubMed Web of Science ®Google Scholar
• Montagna D, Maccario R, Locatelli F, Rosti V, Yang Y, Farness P, . Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood. 2001;98: 3359–66.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Comoli P, Montagna D, Rossi F, Daudt L, Maccario R. Innovative approaches of adoptive immune cell therapy in pediatric recipients of hematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2004;17: 479–92.
   Google Scholar
• Kapp M, Rasche L, Einsle H, Grigoleit GU. Cellular therapy to control tumor progression. Curr Opin Hematol. 2009;16: 437–43.
   Google Scholar
• Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol. 2005;42:799–809.
   PubMed Web of Science ®Google Scholar
• Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126–34.
   PubMed Web of Science ®Google Scholar
• Stamenkovic I. The L-selectin adhesion system. Curr Opin Hematol. 1995;2:68–75.
   Google Scholar
• Nagasawa TA. Chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as a mediator of hematopoiesis. Int J Hematol. 2000;72:408–11.
   Google Scholar
• Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol. 2002;105:117–25.
   PubMed Web of Science ®Google Scholar
• Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PNM. Telomere length dynamics in human lymphocyte subpopulation measured by flow cytometry. Nat Biotechnol. 1998;16:743–7.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhou J, Hatcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30:123–9.
   PubMed Web of Science ®Google Scholar
• Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175: 7046–52.
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, . Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742–51.
   PubMed Web of Science ®Google Scholar